Reni Benjamin Analyst PerformanceAnalyst at Citizens JmpReni Benjamin is a stock analyst at Citizens Jmp focused in the medical sector, covering 43 publicly traded companies. Over the past year, Reni Benjamin has issued 14 stock ratings, including buy and hold recommendations. While full access to Reni Benjamin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Reni Benjamin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings161 Last 11 YearsBuy Recommendations82.69% 129 Buy RatingsCompanies Covered43 Unique Companies Ratings Distribution156RatingsDistribution of strong buy, buy, hold, and sell ratings by Reni Benjamin.RatingPercentageCount Strong Buy0.6%1 ratings Buy82.1%128 ratings Hold16.7%26 ratings Sell0.6%1 ratingsOut of 156 total stock ratings issued by Reni Benjamin at Citizens Jmp, the majority (82.1%) have been Buy recommendations, followed by 16.7% Hold, 0.6% Strong Buy, and 0.6% Sell.Best & Worst CallsBest Call0000.0%RXIIAug 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%EFTRMar 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ86.0% of companies on NASDAQ37 companiesNYSE9.3% of companies on NYSE4 companiesNYSEAMERICAN2.3% of companies on NYSEAMERICAN1 companyOTCMKTS2.3% of companies on OTCMKTS1 companyReni Benjamin, an analyst at Citizens Jmp, currently covers 43 companies listed on NASDAQ, NYSE, NYSEAMERICAN and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical40 companies93.0%Computer and Technology2 companies4.7%Business Services1 company2.3%Reni Benjamin of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and Business Services companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE26 companies60.5%PHARMACEUTICAL PREPARATIONS7 companies16.3%MED - DRUGS2 companies4.7%BIOTECHNOLOGY2 companies4.7%INTERNET SERVICES1 company2.3%MED INSTRUMENTS1 company2.3%FINANCIAL TRANSACTION SERVICES1 company2.3%INTERNET SOFTWARE1 company2.3%MED PRODUCTS1 company2.3%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company2.3% About Reni BenjaminDr. Reni J. Benjamin is an Equity Research Analyst at Citizens JMP Securities LLC. He is on the Board of Directors at Centre For Commercialization of Regenerative Medicine. He is covering biotechnology. He currently serves on the advisory board of Phacilitate Cell & Gene Therapy. Dr. Benjamin joins JMP Securities from Raymond James, where he was a managing director and senior research analyst. Dr. Benjamin was previously a managing director at H.C. Wainwright & Co. and Rodman & Renshaw, after starting his career in biotechnology research at Needham & Company. He is a past member of the UAB School of Health Professions Dean's Advisory Board. Dr. Benjamin holds a Ph.D. in biochemistry and molecular genetics from the University of Alabama at Birmingham and a B.S. in biology from Allegheny College.Follow on LinkedIn Reni Benjamin's Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsPRLDPrelude Therapeutics3/11/2026Boost Price Target$3.60$6.00Market Outperform$0.0000.00% ROIIMMXImmix Biopharma3/9/2026Initiated Coverage$9.29$23.00Outperform$0.0000.00% ROISTROSutro Biopharma1/20/2026Upgrade$13.82$23.00Market Outperform$0.0000.00% ROIALLOAllogene Therapeutics1/9/2026Upgrade$1.49$5.00Outperform$0.0000.00% ROICMPXCompass Therapeutics12/3/2025Set Price Target$5.22$10.00$0.0000.00% ROICMPXCompass Therapeutics12/3/2025Initiated Coverage$5.22$10.00Market Outperform$0.0000.00% ROIBCYCBicycle Therapeutics10/31/2025Set Price Target$8.76$12.00$0.0000.00% ROIBCYCBicycle Therapeutics10/31/2025Boost Price Target$8.76$12.00Market Outperform$0.0000.00% ROIALLOAllogene Therapeutics8/4/2025Reiterated Rating$1.19Market Perform$0.0000.00% ROISANASana Biotechnology6/24/2025Reiterated Rating$2.71$5.00Market Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. KURAKura Oncology6/4/2025Reiterated Rating$6.36$28.00Market Outperform$0.0000.00% ROIBPMCBlueprint Medicines6/3/2025Reiterated Rating$127.69Market Perform$0.0000.00% ROITILInstil Bio6/2/2025Reiterated Rating$33.48Market Perform$0.0000.00% ROISMMTSummit Therapeutics6/2/2025Reiterated Rating$17.30$40.00Market Outperform$0.0000.00% ROILVTXLAVA Therapeutics5/15/2025Reiterated Rating$1.24Market Perform$0.0000.00% ROIINBXInhibrx Biosciences5/15/2025Reiterated Rating$11.84Market Perform$000.0000.00% ROIBCYCBicycle Therapeutics5/2/2025Lower Price Target$9.29$22.00Market Outperform$0.0000.00% ROIPRLDPrelude Therapeutics4/29/2025Reiterated Rating$0.90$4.00Market Outperform$0.0000.00% ROIKURAKura Oncology4/29/2025Reiterated Rating$6.51$28.00Market Outperform$0.0000.00% ROIBPMCBlueprint Medicines2/14/2025Reiterated Rating$95.04$125.00Market Outperform$0.0000.00% ROIINCYIncyte2/11/2025Reiterated Rating$66.47Market Perform$000.0000.00% ROIACETAdicet Bio2/6/2025Reiterated Rating$1.03Market Perform$0.0000.00% ROIKURAKura Oncology2/6/2025Reiterated Rating$8.13$28.00Market Outperform$0.0000.00% ROIUBERUber Technologies2/6/2025Reiterated Rating$67.24Market Perform$00.0000.00% ROISTESTERIS2/6/2025Reiterated Rating$224.65$265.00Market Outperform$000.0000.00% ROIWUWestern Union2/6/2025Reiterated Rating$11.32Market Perform$00.0000.00% ROIWDAYWorkday2/6/2025Reiterated Rating$281.59$315.00Market Outperform$000.0000.00% ROIBPMCBlueprint Medicines1/15/2025Reiterated Rating$107.11$125.00Market Outperform$0.0000.00% ROIINCYIncyte1/14/2025Reiterated Rating$72.37Market Perform$000.0000.00% ROIHOWLWerewolf Therapeutics1/14/2025Lower Price Target$1.35$4.00Market Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupMorgan StanleyRoyal Bank Of CanadaJefferies Financial GroupThe Goldman Sachs GroupStifel NicolausRaymond James FinancialMizuhoBank of AmericaKeyCorpSanford C. BernsteinWolfe ResearchCICC Research Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
